Company Profile
Taysha Gene Therapies Stock Price, News & Analysis
- Ticker:
- TSHA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.34 USD (-1.86%)
Close
Last updated: August 6, 2026
1.64B USD
Market cap
Why the stock is moving
The latest monitored company update is “Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
CNS Gene Therapy Focus
Taysha Gene Therapies is a clinical-stage biotechnology company developing adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system. Its strategy centers on one-time treatments intended to address the underlying genetic cause of disease.
Lead Rett Syndrome Program
The company’s principal candidate, TSHA-102, is an intrathecally delivered AAV9 gene therapy for Rett syndrome. It delivers a functional form of MECP2 and incorporates Taysha’s miRARE auto-regulatory technology, which is designed to control MECP2 expression on a cell-by-cell basis and reduce the risk of overexpression.
Pivotal Development Strategy
TSHA-102 is being evaluated in the REVEAL pivotal trial and the ASPIRE study. Following discussions with the FDA, Taysha has alignment on pivotal design and endpoints and may be able to support a biologics license application using the six-month interim analysis from REVEAL.
Regulatory and Manufacturing Readiness
TSHA-102 has received multiple expedited and orphan designations in the United States, Europe and the United Kingdom. Taysha has also begun a process-performance qualification campaign to establish BLA-enabling manufacturing readiness.
Future catalysts
Longer-term safety and efficacy data from Part A of the REVEAL Phase 1/2 program expected in the second quarter of 2026.
Completion of dosing in the REVEAL pivotal and ASPIRE trials targeted for the second quarter of 2026.
Completion of the TSHA-102 process-performance qualification campaign expected in the fourth quarter of 2026.
Potential BLA submission supported by the six-month interim analysis from the REVEAL pivotal trial.
Recent news
- 01
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Source: Taysha Gene Therapies
- 02
- 03
- 04
- 05
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Source: Taysha Gene Therapies
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Taysha Gene Therapies (TSHA)?
Taysha Gene Therapies (TSHA) most recently closed at 6.34 USD, a -1.86% move versus the previous session.
What is the market cap of Taysha Gene Therapies (TSHA)?
Taysha Gene Therapies currently has a market capitalization of 1.64B USD on BioPharmSignal.
What does Taysha Gene Therapies do?
CNS Gene Therapy Focus Taysha Gene Therapies is a clinical-stage biotechnology company developing adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system. Its strategy centers on one-time treatments intended to address the underlying genetic cause of disease. Lead Rett Syndrome Program The company’s principal...
On which exchange is TSHA stock listed?
Taysha Gene Therapies (TSHA) is associated with NASDAQ, United States, Biopharma.
What is TSHA-102?
Completion of the TSHA-102 process-performance qualification campaign expected in the fourth quarter of 2026.
Which conditions is Taysha Gene Therapies targeting with TSHA-102?
Taysha Gene Therapies is associated with genetic disease based on its company overview and current catalyst commentary.
How does Taysha Gene Therapies describe recent progress with TSHA-102?
Completion of the TSHA-102 process-performance qualification campaign expected in the fourth quarter of 2026.
What is Gene?
CNS Gene Therapy Focus Taysha Gene Therapies is a clinical-stage biotechnology company developing adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system.